These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 22101352)

  • 81. Prognostic and Clinicopathological Significance of ARID1A in Endometrium-Related Gynecological Cancers: A Meta-Analysis.
    Liu G; Xu P; Fu Z; Hua X; Liu X; Li W; Zhang M; Wu J; Wen J; Xu J; Jia X
    J Cell Biochem; 2017 Dec; 118(12):4517-4525. PubMed ID: 28466574
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
    Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
    Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
    [TBL] [Abstract][Full Text] [Related]  

  • 83. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.
    Werner HM; Berg A; Wik E; Birkeland E; Krakstad C; Kusonmano K; Petersen K; Kalland KH; Oyan AM; Akslen LA; Trovik J; Salvesen HB
    Mod Pathol; 2013 Mar; 26(3):428-34. PubMed ID: 23080032
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
    Davidson B; Trope' CG; Wang TL; Shih IeM
    Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Recently identified drug resistance biomarkers in ovarian cancer.
    Davidson B
    Expert Rev Mol Diagn; 2016; 16(5):569-78. PubMed ID: 26895188
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
    Kim M; Lu F; Zhang Y
    Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
    Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
    J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
    [TBL] [Abstract][Full Text] [Related]  

  • 88. MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.
    Makii C; Oda K; Ikeda Y; Sone K; Hasegawa K; Uehara Y; Nishijima A; Asada K; Koso T; Fukuda T; Inaba K; Oki S; Machino H; Kojima M; Kashiyama T; Mori-Uchino M; Arimoto T; Wada-Hiraike O; Kawana K; Yano T; Fujiwara K; Aburatani H; Osuga Y; Fujii T
    Oncotarget; 2016 Nov; 7(46):75328-75338. PubMed ID: 27659536
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
    Vogel TJ; Goodman MT; Li AJ; Jeon CY
    Gynecol Oncol; 2017 Aug; 146(2):340-345. PubMed ID: 28596017
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
    Sugiyama T; Kamura T; Kigawa J; Terakawa N; Kikuchi Y; Kita T; Suzuki M; Sato I; Taguchi K
    Cancer; 2000 Jun; 88(11):2584-9. PubMed ID: 10861437
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Association between Molecular Genetic Markers of DNA Repair and Cell Cycle Control Genes and Response to Platinum-Based Chemotherapy in Ovarian Cancer Patients.
    Zavarikina TM; Khokhlova SV; Tyulyandina AS; Khabas GN; Asaturova AV; Nosova YV; Brenner PK; Kapralova MA; Khodirev DS; Stenina MB
    Bull Exp Biol Med; 2021 Oct; 171(6):755-759. PubMed ID: 34709513
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary.
    Choi CH; Sung CO; Kim HJ; Lee YY; Song SY; Song T; Kim J; Kim TJ; Lee JW; Bae DS; Kim BG
    Hum Pathol; 2013 Jun; 44(6):1017-23. PubMed ID: 23290009
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.
    Wang Q; Wang L; L Y; Ding X; Liu A
    J BUON; 2017; 22(5):1314-1321. PubMed ID: 29135119
    [TBL] [Abstract][Full Text] [Related]  

  • 94. ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2.
    Luo Q; Wu X; Zhang Y; Shu T; Ding F; Chen H; Zhao P; Chang W; Zhu X; Liu Z
    Cancer Lett; 2018 Jul; 427():9-17. PubMed ID: 29660381
    [TBL] [Abstract][Full Text] [Related]  

  • 95. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas.
    Allo G; Bernardini MQ; Wu RC; Shih IeM; Kalloger S; Pollett A; Gilks CB; Clarke BA
    Mod Pathol; 2014 Feb; 27(2):255-61. PubMed ID: 23887303
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.
    Canet B; Pons C; Espinosa I; Prat J
    Hum Pathol; 2011 Jun; 42(6):833-9. PubMed ID: 21208644
    [TBL] [Abstract][Full Text] [Related]  

  • 97.
    Kawahara N; Yamada Y; Kobayashi H
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.
    Goldman AR; Bitler BG; Schug Z; Conejo-Garcia JR; Zhang R; Speicher DW
    Mol Cell Proteomics; 2016 Nov; 15(11):3348-3360. PubMed ID: 27654507
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma.
    Mao TL; Ardighieri L; Ayhan A; Kuo KT; Wu CH; Wang TL; Shih IeM
    Am J Surg Pathol; 2013 Sep; 37(9):1342-8. PubMed ID: 24076775
    [TBL] [Abstract][Full Text] [Related]  

  • 100. How Progesterone Receptor Expression Impacts Platinum Sensitivity in Ovarian Clear Cell Carcinoma: Insights from Clinical and Experimental Perspectives.
    Wu CH; Fu HC; Ou YC; Chuang IC; Lan J; Yang MY; Lin H
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.